Drug intelligence / Profile preview

APO-2F

Development stage: Unknown
Lead developer: Aposcience
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Topical

Overview

APO2FOOT is a clinical-stage, cell-free biological medicinal product developed by Aposcience for the treatment of chronic diabetic foot ulcers (DFU). The program is based on APOSEC, which is the cell-free secretome of irradiated, stress-conditioned allogeneic peripheral blood mononuclear cells (PBMC). Specifically, the APO2FOOT program utilizes the optimized final product formulation, APO-2F, delivered on an alginate fleece or hydrogel. APOSEC contains a complex mixture of cytokines, growth factors, lipids, and exosomes that act synergistically to promote angiogenesis, modulate the immune system, and enhance tissue repair, thereby accelerating wound healing.

Other names: APO2FOOTAPO-2FOOTAPO 2FOOTAPOSEC

Beyond the preview

Go deeper on APO-2F.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APO-2F.

Explore the full profile